CPSE:NOVO BPharmaceuticals
Novo Nordisk (CPSE:NOVO B) Could Be 12% Overvalued As Wegovy Access Expands
Novo Nordisk (CPSE:NOVO B) is back in the spotlight after the Medicare GLP-1 Bridge expanded access to Wegovy in the US, while fresh semaglutide data and delivery partnerships continue to focus attention on the company’s obesity franchise.
See our latest analysis for Novo Nordisk.
The Medicare GLP-1 Bridge, fresh Wegovy approvals, and the Vivani implant evaluation have coincided with a 30-day share price return of 13.83% and a 90-day share price return of 33.91% for Novo Nordisk. Over the...